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Background: In the last years, levothyroxine (LT4) has been commercialized also in 
liquid formulation, which is less sensitive to the factors known to reduce the absorption 
of tablet LT4. To date, there is no robust information that liquid LT4 can improve pharma-
cologic thyroid homeostasis of patients with reduced efficacy of tablet LT4. This analysis 
aimed at achieving solid evidence that switching thyroxine treatment from tablet to liquid 
preparation improves patients’ TSH levels.
methods: The search was performed in PubMed/MEDLINE and Scopus database 
based on the terms “thyroid,” “levothyroxine,” and “liquid,” and updated until September 
25, 2017. Studies were included only if they described patients with suboptimal TSH on 
tablet LT4, subsequently switched to liquid LT4.
Results: The literature search retrieved 462 articles and six were finally included. The 
pooled mean difference of TSH value between tablet and liquid LT4 was 4.23 mIU/L (95% 
CI from 3.69 to 4.77). Mild heterogeneity was found (I2 60%). Overall mean difference of 
TSH was significant (p < 0.0001).
conclusion: The present meta-analysis showed that patients with suboptimal TSH on 
tablet LT4 can have a significantly improved TSH by switching to liquid LT4 formulation 
at unchanged dose.
Keywords: thyroxine absorption, oral liquid levothyroxine, thyroxine malabsorption, drugs dissolution, 
gastrointestinal disorders
iNtRODUctiON
Rationale
Levothyroxine (LT4) is one of the most prescribed drugs worldwide and is characterized by a narrow 
therapeutic index (1). Therefore, this drug would require a careful dose individualization (2, 3) to avoid 
side effects of iatrogenic hyper- and hypothyroidism, even in their subclinical form (4). Generally, the 
efficacy of LT4 is evaluated by serum TSH value as it is considered the most accurate measurement 
of thyroid pharmacological homeostasis, and usually physician assess in each patient a specific TSH 
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target to be reached and maintained. However, the desired TSH 
may be not reached in about one patient out of two (5). Indeed, 
even if a dose of 1.6–1.8 mcg/kg/day of LT4 should be satisfactory 
to treat hypothyroid patients (6), a non-negligible rate of them 
would require a dose increased up to 30–40% (7, 8). Several factors 
may influence the achievement of the target TSH. Some of these 
are patient/physician dependent, such as the prescribed dose, the 
LT4 intake schedule, and the patient’s compliance (9). In addition, 
several studies investigated systematically the LT4 ineffectiveness 
and demonstrated that intestinal disorders (i.e., celiac disease, lac-
tose intolerance, dysbiosis) (10–13), gastric diseases (i.e., chronic 
atrophic gastritis, Helicobacter pylori infection) (7, 14), and con-
comitant intake of some drugs or ingestion of food or beverages 
(15, 16) can interfere with the LT4 absorption, thus reducing its 
efficacy. Notably, the failure to achieve the therapeutic target can 
determine multiple dosage adjustments, with consequent increase 
of health-care resources costs by up to 84% (17).
Objectives
Almost all studies focusing on LT4 efficacy evaluated the per-
formance of its tablet formulation, which is the traditional one. 
In the last decade, due to the abovementioned interferences, the 
pharmaceutical research developed new LT4 formulations, such 
as softgel capsule and liquid preparations, which have become 
available in a growing number of countries. These formulations 
are bioequivalent as compared to the traditional one but are 
characterized by different excipients; in fact, the active ingredient 
is dissolved in glycerin and surrounded by a gelatin shell (softgel 
capsule) or dissolved in glycerin and ethanol (liquid solution) 
(18). The main goal of softgel capsule and liquid solution use 
is to overcome the tablet LT4 dissolution problems (18, 19). 
This raised interesting outlook and some authors investigated 
the effectiveness of softgel and liquid LT4 with different study 
designs. Interestingly, liquid LT4 has been proven to be quickly 
absorbed because of its physical status: in fact, it does not require 
the dissolution phase, which is instead a necessary step for tablet 
(solid phase) absorption (19). Also, the issue whether the liquid 
LT4 efficacy is impaired by breakfast/coffee was investigated 
in six prospective studies (20–25), including one double-blind 
placebo controlled trial (24), one with a cross-over design (22), 
and one which evaluated the efficacy of the switch between liquid 
and softgel formulations (25); there, it was clearly demonstrated 
that liquid LT4 efficacy is not influenced by the lag time between 
breakfast and drug ingestion. On the contrary, the actual reli-
ability of liquid LT4 in treating patients with not optimal TSH 
during therapy with traditional tablet formulation due to gastro-
intestinal diseases, polypharmacy, or not definitely demonstrated 
LT4 malabsorption remains not yet assessed. In fact, most of the 
studies showed heterogeneous designs in limited patients’ series, 
thus hampering the achievement of solid evidence.
Research Question
Therefore, the lack of definite proofs that liquid LT4 can improve 
pharmacological thyroid homeostasis, prompted us to review the 
targeted literature. The present study was aimed at systematically 
review the literature to strengthen evidence that, in patients with 
reduced efficacy of tablet LT4, serum TSH can be normalized 
by switching therapy to liquid preparation. Based on the results 
found, we also attempted to perform a meta-analysis of retrieved 
data.
mateRiaLS aND metHODS
Study Design
The study design included studies investigating the efficacy of 
liquid LT4 in the treatment of hypothyroidism in two online 
databases.
Participants, interventions, comparators
Participants were patients treated with tablet LT4 and having not 
optimal TSH, and switched to liquid LT4 with unchanged LT4 
dose. There was no comparator.
Search Strategy
A comprehensive computer literature search of the PubMed/
MEDLINE and Scopus databases was conducted to find published 
articles on this topic. The search algorithm was based on the 
combinations of the terms “thyroid” AND “levothyroxine” AND 
“liquid.” A beginning date limit was not used, and the search was 
updated until September 21, 2017. No language restriction was 
adopted. To identify additional studies and expand our search, 
references lists of the retrieved articles could be screened. Two 
investigators (CV and PT) independently searched articles apply-
ing this strategy.
Data Sources, Studies Sections,  
and Data extraction
Original articles reporting experience on the use of liquid LT4 
in humans were initially eligible for the systematic review. We 
selected studies according to the following criteria: studies were 
included if they reported patients with TSH levels higher than the 
upper reference value on tablet LT4 and then addressed to switch 
to liquid LT4. As exclusion criteria, studies were not included 
if they described a series of patients smaller than 10 cases 
(i.e., case report and cases series), used different dose of liquid 
LT4 with respect to that of tablet LT4, described the use of a non-
pharmaceutically produced liquid preparation, included only 
patients requiring a specific TSH value (i.e., patients followed-up 
for differentiated thyroid carcinomas in whom TSH target may 
depend on the risk category of each case). In addition, articles 
with unclear data, and series with overlapping data were excluded. 
The same two authors (CV and PT) independently screened titles 
and abstracts of the retrieved articles according to the above cri-
teria, reviewed the full-texts, and selected articles for their final 
inclusion. For each included study, information was extracted 
concerning study data: authors, year of publication, journal, study 
aim, study design, main results, and country of patients’ origin. 
Age of patients enrolled in the studies was also collected, when 
available.
Data analysis
Statistical analysis was performed using the Review Manager 
(RevMan) version 5.3 (Computer program; Copenhagen: The 
FigURe 1 | Diagram of flow of search strategy and results.
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Nordic Cochrane Centre, The Cochrane Collaboration, 2014). 
According to the Cochrane handbook, statistical analysis was 
conducted as generic inverse variance, mean difference was 
considered as the effect measure and 95% confidence interval 
(95% CI) was calculated for totals and each study. According 
to these criteria, the mean difference and SE of TSH value on 
tablet LT4 minus that on liquid LT4 (at least 2 months therapy) 
was obtained for each group or subgroup included for the meta-
analysis. When TSH data were not available in a PDF paper, the 
authors were contacted directly. Thus, the pooled TSH mean 
difference (and 95% CI) was calculated and the fixed effect model 
was used. I-square index was used to quantify the heterogeneity 
among the studies, and the absence of significant heterogeneity 
was defined as an I-square value <50%. Statistical significance 
of the overall result was analyzed by test for overall effect. The 
assessment of risk of bias was made by two authors (CV and PT) 
according to the Cochrane handbook; they evaluated the quality 
of the included studies based on their design, presence of car-
ryover effect, data analysis performed, and reporting of results. 
Statistical significance was set at p < 0.05.
ReSULtS
Study Selection and characteristics
The comprehensive computer literature search retrieved 369 
articles from PubMed/MEDLINE and 93 papers from Scopus 
database. Once excluded duplicates articles, the papers initially 
included were 13. Abstracts of these articles were screened and 
7 (21, 26–31) were excluded according to the abovementioned 
criteria [4 reported small series (26, 28–30), 1 included patients 
showing the effect of switching T4 treatment in patients, which had 
already reached normal TSH with traditional tablet formulation 
(27), one described the use of a non-pharmaceutically produced 
liquid preparation (31), one enrolled only differentiated thyroid 
carcinoma patients (21)]. Finally, the systematic review included 
six original articles (32–37). Figure 1 illustrates the diagram of 
flow to retrieve the final series of papers.
Synthesized analysis
The included papers were published from 2014 to 2017 (32–37), 
and authors were Italian in all cases. All these studies had a 
prospective design; analyzed patients were already on tablet LT4 
treatment without reaching optimal TSH values. Afterward, all 
subjects have been switched to liquid LT4 and the change of 
serum TSH values have been evaluated after 2 months. Overall, 
a number of 141 patients were described. Notably, all these stud-
ies modified LT4 therapy from tablet to liquid formulation with 
unchanged dose. Possible overlapping of data was excluded by 
contacting the authors. Table 1 summarizes the characteristics of 
these studies. The pooled mean difference of TSH value between 
tablet LT4 and liquid LT4 was 4.23 mIU/L (95% CI from 3.69 to 
4.77). Considering the single studies, TSH levels were reduced 
after liquid LT4 in all cases with a mean difference from 1.87 to 
5.70 mIU/L. Mild heterogeneity between the studies was found 
(I2 60%). Overall mean difference of TSH was significant as 
showed by test of overall effect (p < 0.0001) (Figure 2).
Risk of Bias
Risk of bias was assessed by four issues and results of each study 
reported in Figure 2. Three papers had a study design showing 
higher risk of bias, other three were at risk for their reporting, and 
one paper was assessed at higher risk of carryover.
DiScUSSiON
Summary of Findings
Here, we systematically reviewed the available literature on the 
use of liquid solution LT4 in patients previously treated with 
tablet LT4. Our search allowed retrieving six studies reporting 
data about 141 patients. Notably, all these articles described a 
FigURe 2 | Forest plot of meta-analysis (fixed-effect) of six studies reporting patients who switched from tablet to liquid levothyroxine (LT4). Mean difference was 
referred to TSH levels (i.e., mean TSH on tablet LT4 minus mean TSH on liquid LT4). One study (36) described two subgroups of patients, and we excluded that of 
four cases according to the studies selection criteria (see Materials and Methods). Risk of bias assessment was represented as green when there was low risk, red 
when there was high risk, and white when the risk was unclear.
taBLe 1 | Overview of the studies included in the present review.
Reference year Study type Patients type Patients who completed  
the study (n)
Vita et al. (32) 2014 Prospective Patients taking levothyroxine (LT4) concomitantly with PPI 24
Brancato et al. (33) 2014 Prospective Hypothyroid patients with elevated TSH on tablet LT4 53
Fallahi et al. (34) 2016 Prospective Patients with subclinical hypothyroidism treated with tablet LT4 not reaching optimal 
TSH despite not known causes of malabsorption
21
Benvenga et al. (35) 2017 Prospective Patients with tablet LT4 malabsorption caused by calcium and/or iron supplements 19
Fallahi et al. (36)a 2017 Prospective Hypothyroid patients, treated with tablet LT4, undergone bariatric surgery of Roux-
en-Y gastric bypasses
13
Vita et al. (37) 2017 Prospective Patients with T4 malabsorption due to concomitant use of multiple drugs 11
Articles appear in the table by the year of publication. All studies switched patients from tablet to liquid LT4 at unchanged dose.
aThis study described two subgroups of patients, and we excluded that of four cases according to the studies selection criteria (see Materials and Methods).
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significant decrease of TSH levels after switching from tablet to 
liquid LT4, leaving the dose unchanged. Analyzing the pooled 
results, we found that the mean difference of TSH decrease was 
4.23  mIU/L, and this finding showed a strong statistical sig-
nificance. The six studies included in our meta-analysis enrolled 
patients who switched to liquid LT4 because of different reasons, 
mainly represented by malabsorption; in the manuscripts 
included, the authors selected their patients with suboptimal 
TSH, switched LT4 preparation, and obtained the improvement 
of serum TSH values. All these data suggest that the use of liquid 
LT4 preparation can reduce TSH levels obtained with the same 
dose of tablet LT4 and the present meta-analysis reinforces this 
evidence.
Some other papers initially eligible but afterward excluded 
from our study (21, 26–31) gave important information about 
this topic: almost all articles described the efficacy on reaching 
optimal TSH values in patients previously undertreated with 
tablet T4 formulation as depicted in Table  2. Interestingly, the 
paper describing the largest series of patients (27) showed the 
reduction of TSH levels after the switch to liquid solution even 
in patients without malabsorption and already with optimal 
serum thyroid balance on tablet LT4. Noteworthy, in a study (21) 
enrolling only highly selected and cured patients with differenti-
ated thyroid cancers, switched from tablet to liquid LT4, it has 
been shown a significant reduction of subjective symptoms with 
overlap of therapeutic effectiveness. This finding might indirectly 
prompt physicians to use a dose of liquid LT4 lower than one 
could estimate with tablet formulation, similarly to that proposed 
for softgel preparation in a recent study (38).
Limitations
The reliability of liquid LT4 in reducing TSH levels of tablet 
T4-treated patients should be ideally evaluated with randomized 
controlled trials (RCT) with a cross-over design. One RCT was 
published on the use of liquid LT4 and proved the efficacy of this 
formulation, even in the case of T4 ingestion concomitant with 
breakfast (25), independently from its composition. The same 
result has been described in a crossover study by Morelli et al. 
(22). The six papers found by the present systematic review had a 
design quite similar to a cross-over study. A selection bias might 
be present in this meta-analysis because the included papers did 
not select patients prior to begin tablet LT4 treatment. In fact, the 
patients enrolled were already on tablet LT4 treatment, because 
these studies were aimed at comparing the performance of liquid 
taBLe 2 | Overview of the eligible studies subsequently excluded from the present review.
Reference year Study type Patients type Patients who completed  
the study (n)
Pirola et al. (26) 2014 Prospective Hypothyroid patients, treated with tablet levothyroxine (LT4), undergone 
bariatric surgery
4
Giusti et al. (21) 2014 Prospective Thyroidectomized for differentiated thyroid cancer 54
Fallahi et al. (27) 2016 Prospective Patients with optimal TSH values during tablet T4 treatment 141
Fallahi et al. (28) 2016 Prospective Patients with autoimmune atrophic gastritis 5
Fallahi et al. (29) 2017 Prospective Patients with lactose intolerance 5
Peirce et al. (30) 2017 Prospective Thyroidectomized patients 3
Hommel and Delgrange (31) 2017 Prospective Hypothyroid patient, treated with tablet LT4, undergone bariatric surgery 1
Articles appear in the table by the year of publication. All studies switched patients from tablet to liquid LT4 at unchanged dose. These studies were excluded from our analysis 
according to the studies selection criteria (see Materials and Methods).
5
Virili et al. Liquid LT4
Frontiers in Endocrinology | www.frontiersin.org January 2018 | Volume 9 | Article 10
over tablet LT4 in improving suboptimal TSH of these patients. 
Also, this design shows several advantages: each participant acted 
as her/his own control eliminating among-participant variation, 
addressing the problem of statistical power, and every partici-
pant received both interventions. The main problem associated 
with this study design is that of carryover, such as the situation 
in which the effects of the first intervention given (tablet LT4 in 
our case) keep on the subsequent period, thus interfering with 
the effects of the second intervention (liquid LT4). To skip this 
problem, some cross-over trials may decide to include a period 
between interventions known as a washout period. However, 
here, we are confident to exclude a carryover effect because we 
considered in our analysis only TSH value on tablet LT4 and 
2 months after the switch to liquid formulation. Among other 
potential limitations of the present data, we meta-analyzed here 
studies published very recently and with no large sample size. 
Generally, studies reporting preliminary results, in small series, 
and with positive findings are more likely to be published. As a 
final remark, only Italian authors published on this topic due to 
the large availability of liquid LT4 in our country. These findings 
have to be verified in other countries and in populations with 
different habits, which could influence the effect of different 
thyroxine preparations.
conclusion
In conclusion, the present meta-analysis supports the evidence 
that, in tablet LT4-treated patients with suboptimal TSH, one 
can obtain a lower TSH value by switching therapy to liquid LT4 
formulation at unchanged dose. This may be of interest in clinical 
practice in patients with refractory hypothyroidism.
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